Drug prices · Published November 7, 2026
Xarelto: Medicare's negotiated price is 62% below its 2023 list price
From January 1, 2026, Medicare drug plans pay $197 for a 30-day supply of Xarelto (rivaroxaban), the price CMS negotiated with Johnson & Johnson. The 2023 list price was $517. What a person with Medicare pays depends on their Part D plan, and Part D out-of-pocket drug costs are capped at $2,100 in 2026.
62%below the 2023 list price
| Price | 30-day supply |
|---|---|
| 2023 list price (wholesale acquisition cost) | $517 |
| Medicare negotiated price, from Jan 1, 2026 | $197 |
How we calculated this
Both figures are from the CMS fact sheet on negotiated prices for 2026. A list price is before rebates and discounts; neither figure is what a patient pays at the pharmacy.
Sources
This story is a snapshot from November 7, 2026; current prices are on the linked pages.